NewsPress Releases

BOSTON, December 18, 2018 – From Omaha to Pakistan, Etiometry has doubled their client base in the last year. These new partnerships are placing the Etiometry Platform beside hundreds of beds, and empowering clinicians to make data-driven decisions on more than tens of thousands of patients per year. “Every partnership is a chance to improve countless outcomes for patients at the most critical point in their care. We are honored to work with the top academic medical centers in the world and we strive to make our software the industry standard,” explained Etiometry’s COO Evan Butler. 

As the company continues to gain momentum as the industry leader in dynamic analytics for critical care, they’ve got a new focus for partners in 2019. Since earning FDA clearance on their first Risk Analytics Algorithm for neonates in 2016, the company has been committed to expanding this potentially life-saving software to a larger audience. According to Etiometry CTO Dr. Dimitar Baronov, “Rather than creating isolated algorithms to estimate adverse patient outcomes, Etiometry’s innovative technology allows the company to comprehensively and continuously track physiologic risks, which enables the care teams to avoid patient harm.” Etiometry’s T3 Software is cleared for patients of any age; however, the company’s current FDA clearance for the IDO2 Index allows use on patients ages 12 and under. Etiometry is in the process of obtaining FDA clearance for adult patients and is currently accepting research partnerships with academic medical centers specializing in adult medicine.

About Etiometry

Etiometry Inc. is the leader in clinical decision-support software for the intensive care environment. Our technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patient condition to avoid complications and speed recovery. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering costs of care through the more effective use of all available data.

For more information, visit